Mitral Regurgitation Clinical Trial
— EVERESTIIRCTOfficial title:
Pivotal Study: A Study of the Evalve Cardiovascular Valve Repair System - Endovascular Valve Edge-to-Edge REpair STudy (EVERESTIIRCT)
| Verified date | November 2018 |
| Source | Abbott Medical Devices |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
EVEREST II Randomized Controlled Trial (RCT) is a prospective, multi-center, randomized study of the MitraClip® System in the treatment of mitral valve regurgitation, randomizing patients to MitraClip or mitral valve surgery. The EVEREST II High Risk Registry (HRR) study is a prospective multi-center study of the MitraClip System for the treatment of mitral valve regurgitation in high surgical risk patients. Enrollment in the RCT and HRR is closed. A continued access prospective, multi-center study (REALISM) of the MitraClip System in a surgical population (non-high risk arm) and a high surgical risk population (high risk arm) is ongoing. Enrollment in the non-high risk arm of REALISM is closed. Enrollment in the high risk arm of REALISM is ongoing. Patients enrolled in EVEREST II undergo 30-day, 6-month, 12-month, 18-month and 24-month clinical and echocardiographic follow-up, and then annually for 5 years.
| Status | Completed |
| Enrollment | 279 |
| Est. completion date | December 2014 |
| Est. primary completion date | November 2009 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Key Inclusion/Exclusion Criteria: Patients with Grade 3 (moderate to severe) or Grade 4 (severe) mitral regurgitation (MR) based on American Society of Echocardiography guidelines: - Are 18 years or older. - Symptomatic - If asymptomatic, must have new onset of atrial fibrillation, pulmonary hypertension, or evidence of left ventricular dysfunction - Are candidates for mitral valve surgery - Are candidates for transseptal catheterization - Primary regurgitant jet must originate from malcoaptation of the A2 and P2 scallops of the mitral valve - Appropriate valve anatomy for MitraClip - Does not need other cardiac surgery or any emergency surgery - Did not experience myocardial infarction in prior 12 weeks or endovascular procedure in prior 30 days - Mitral valve orifice area = 4 cm2 - Do not have renal insufficiency - Echocardiographic evidence of intracardiac mass, thrombus or vegetation |
| Country | Name | City | State |
|---|---|---|---|
| United States | Evanston Northwestern Healthcare | Evanston | Illinois |
| Lead Sponsor | Collaborator |
|---|---|
| Abbott Medical Devices |
United States,
Argenziano M, Skipper E, Heimansohn D, Letsou GV, Woo YJ, Kron I, Alexander J, Cleveland J, Kong B, Davidson M, Vassiliades T, Krieger K, Sako E, Tibi P, Galloway A, Foster E, Feldman T, Glower D; EVEREST Investigators. Surgical revision after percutaneous mitral repair with the MitraClip device. Ann Thorac Surg. 2010 Jan;89(1):72-80; discussion p 80. doi: 10.1016/j.athoracsur.2009.08.063. — View Citation
Biner S, Siegel RJ, Feldman T, Rafique AM, Trento A, Whitlow P, Rogers J, Moon M, Lindman B, Zajarias A, Glower D, Kar S; EVEREST investigators. Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. Eur J Heart Fail. 2012 Aug;14(8):939-45. Epub 2012 May 14. — View Citation
Borgia F, Di Mario C, Franzen O. Adenosine-induced asystole to facilitate MitraClip placement in a patient with adverse mitral valve morphology. Heart. 2011 May;97(10):864. doi: 10.1136/hrt.2010.208132. Epub 2010 Oct 29. — View Citation
Cikirikcioglu M, Cherian S, Schussler O, Kalangos A. Regarding "The EVEREST II Trial: design and rationale for a randomized study of the Evalve MitraClip system compared with mitral valve surgery for mitral regurgitation". Am Heart J. 2011 Jul;162(1):e11-2; author reply e13. doi: 10.1016/j.ahj.2011.04.004. Epub 2011 Jun 12. — View Citation
Cohn LH. Percutaneous mitral valve repair with the edge-to-edge technique: a surgeon's perspective. J Am Coll Cardiol. 2005 Dec 6;46(11):2141-2. Epub 2005 Oct 17. — View Citation
Condado JA, Acquatella H, Rodriguez L, Whitlow P, Vélez-Gimo M, St Goar FG. Percutaneous edge-to-edge mitral valve repair: 2-year follow-up in the first human case. Catheter Cardiovasc Interv. 2006 Feb;67(2):323-5. — View Citation
Condado JA, Vélez-Gimón M. Catheter-based approach to mitral regurgitation. J Interv Cardiol. 2003 Dec;16(6):523-34. Review. — View Citation
Dang NC, Aboodi MS, Sakaguchi T, Wasserman HS, Argenziano M, Cosgrove DM, Rosengart TK, Feldman T, Block PC, Oz MC. Surgical revision after percutaneous mitral valve repair with a clip: initial multicenter experience. Ann Thorac Surg. 2005 Dec;80(6):2338- — View Citation
Fann JI, St Goar FG, Komtebedde J, Oz MC, Block PC, Foster E, Butany J, Feldman T, Burdon TA. Beating heart catheter-based edge-to-edge mitral valve procedure in a porcine model: efficacy and healing response. Circulation. 2004 Aug 24;110(8):988-93. Epub 2004 Aug 9. — View Citation
Fann JI, St Goar FG. Percutaneous aortic valve replacement and mitral valve repair. Future Cardiol. 2005 May;1(3):393-403. doi: 10.1517/14796678.1.3.393. — View Citation
Feldman T, Glower D. Patient selection for percutaneous mitral valve repair: insight from early clinical trial applications. Nat Clin Pract Cardiovasc Med. 2008 Feb;5(2):84-90. doi: 10.1038/ncpcardio1068. Review. — View Citation
Feldman T, Kar S, Rinaldi M, Fail P, Hermiller J, Smalling R, Whitlow PL, Gray W, Low R, Herrmann HC, Lim S, Foster E, Glower D; EVEREST Investigators. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009 Aug 18;54(8):686-94. doi: 10.1016/j.jacc.2009.03.077. — View Citation
Feldman T, Wasserman HS, Herrmann HC, Gray W, Block PC, Whitlow P, St Goar F, Rodriguez L, Silvestry F, Schwartz A, Sanborn TA, Condado JA, Foster E. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase — View Citation
Foster E, Kwan D, Feldman T, Weissman NJ, Grayburn PA, Schwartz A, Rogers JH, Kar S, Rinaldi MJ, Fail PS, Hermiller J, Whitlow PL, Herrmann HC, Lim DS, Glower DD; EVEREST Investigators. Percutaneous mitral valve repair in the initial EVEREST cohort: evide — View Citation
Glower D, Ailawadi G, Argenziano M, Mack M, Trento A, Wang A, Lim DS, Gray W, Grayburn P, Dent J, Gillam L, Sethuraman B, Feldman T, Foster E, Mauri L, Kron I; EVEREST II Investigators. EVEREST II randomized clinical trial: predictors of mitral valve repl — View Citation
Herrmann HC, Gertz ZM, Silvestry FE, Wiegers SE, Woo YJ, Hermiller J, Segar D, Heimansohn D, Gray W, Homma S, Argenziano M, Wang A, Jollis J, Lampert MB, Alexander J, Mauri L, Foster E, Glower D, Feldman T. Effects of atrial fibrillation on treatment of m — View Citation
Herrmann HC, Kar S, Siegel R, Fail P, Loghin C, Lim S, Hahn R, Rogers JH, Bommer WJ, Wang A, Berke A, Lerakis S, Kramer P, Wong SC, Foster E, Glower D, Feldman T; EVEREST Investigators. Effect of percutaneous mitral repair with the MitraClip device on mitral valve area and gradient. EuroIntervention. 2009 Jan;4(4):437-42. — View Citation
Herrmann HC, Rohatgi S, Wasserman HS, Block P, Gray W, Hamilton A, Zunamon A, Homma S, Di Tullio MR, Kraybill K, Merlino J, Martin R, Rodriguez L, Stewart WJ, Whitlow P, Wiegers SE, Silvestry FE, Foster E, Feldman T. Mitral valve hemodynamic effects of pe — View Citation
Lim DS, Kunjummen BJ, Smalling R. Mitral valve repair with the MitraClip device after prior surgical mitral annuloplasty. Catheter Cardiovasc Interv. 2010 Sep 1;76(3):455-9. doi: 10.1002/ccd.22547. — View Citation
Luk A, Butany J, Ahn E, Fann JI, St Goar F, Thornton T, McDermott L, Madayag C, Komtebedde J. Mitral repair with the Evalve MitraClip device: histopathologic findings in the porcine model. Cardiovasc Pathol. 2009 Sep-Oct;18(5):279-85. doi: 10.1016/j.carpath.2008.07.001. Epub 2008 Aug 13. — View Citation
Mauri L, Foster E, Glower DD, Apruzzese P, Massaro JM, Herrmann HC, Hermiller J, Gray W, Wang A, Pedersen WR, Bajwa T, Lasala J, Low R, Grayburn P, Feldman T; EVEREST II Investigators. 4-year results of a randomized controlled trial of percutaneous repair — View Citation
Mauri L, Garg P, Massaro JM, Foster E, Glower D, Mehoudar P, Powell F, Komtebedde J, McDermott E, Feldman T. The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral reg — View Citation
Pope NH, Lim S, Ailawadi G. Late calcific mitral stenosis after MitraClip procedure in a dialysis-dependent patient. Ann Thorac Surg. 2013 May;95(5):e113-4. doi: 10.1016/j.athoracsur.2012.10.067. — View Citation
Rogers JH, Yeo KK, Carroll JD, Cleveland J, Reece TB, Gillinov AM, Rodriguez L, Whitlow P, Woo YJ, Herrmann HC, Young JN. Late surgical mitral valve repair after percutaneous repair with the MitraClip system. J Card Surg. 2009 Nov-Dec;24(6):677-81. doi: 10.1111/j.1540-8191.2009.00901.x. Epub 2009 Jul 24. — View Citation
Silvestry FE, Rodriguez LL, Herrmann HC, Rohatgi S, Weiss SJ, Stewart WJ, Homma S, Goyal N, Pulerwitz T, Zunamon A, Hamilton A, Merlino J, Martin R, Krabill K, Block PC, Whitlow P, Tuzcu EM, Kapadia S, Gray WA, Reisman M, Wasserman H, Schwartz A, Foster E — View Citation
Smith T, McGinty P, Bommer W, Low RI, Lim S, Fail P, Rogers JH. Prevalence and echocardiographic features of iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip system. Catheter Cardiovasc Interv. 2012 Oct 1;80(4):6 — View Citation
St Goar FG, Fann JI, Komtebedde J, Foster E, Oz MC, Fogarty TJ, Feldman T, Block PC. Endovascular edge-to-edge mitral valve repair: short-term results in a porcine model. Circulation. 2003 Oct 21;108(16):1990-3. Epub 2003 Oct 6. — View Citation
Tamburino C, Immè S, Barbanti M, Mulè M, Pistritto AM, Aruta P, Cammalleri V, Scarabelli M, Mangiafico S, Scandura S, Ussia GP. Reduction of mitral valve regurgitation with Mitraclip® percutaneous system. Minerva Cardioangiol. 2010 Oct;58(5):589-98. — View Citation
Tamburino C, Ussia GP, Maisano F, Capodanno D, La Canna G, Scandura S, Colombo A, Giacomini A, Michev I, Mangiafico S, Cammalleri V, Barbanti M, Alfieri O. Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting. Eur Heart J. 2010 Jun;31(11):1382-9. doi: 10.1093/eurheartj/ehq051. Epub 2010 Mar 18. — View Citation
Whitlow PL, Feldman T, Pedersen WR, Lim DS, Kipperman R, Smalling R, Bajwa T, Herrmann HC, Lasala J, Maddux JT, Tuzcu M, Kapadia S, Trento A, Siegel RJ, Foster E, Glower D, Mauri L, Kar S; EVEREST II Investigators. Acute and 12-month results with catheter — View Citation
* Note: There are 30 references in all — Click here to view all references
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants With Major Adverse Events (MAE) | Defined as a combined clinical endpoint of death, myocardial infarction, reoperation for failed surgical repair or replacement, nonelective cardiovascular surgery for adverse events, stroke, renal failure, deep wound infection, ventilation for greater than 48 hours, gastrointestinal (GI) complication requiring surgery, new onset of permanent atrial fibrillation, septicemia, and transfusion of 2 or more units of blood. | 30 days | |
| Primary | Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR). | 12 months | ||
| Secondary | Freedom From All-Cause Mortality | 12 months | ||
| Secondary | Freedom From All-Cause Mortality | 24 months | ||
| Secondary | Freedom From All-Cause Mortality | 3 years | ||
| Secondary | Freedom From All-Cause Mortality | 4 years | ||
| Secondary | Freedom From All-Cause Mortality | 5 years | ||
| Secondary | Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation. | 12 months | ||
| Secondary | Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR). | 24 months | ||
| Secondary | Number of Participants With Freedom From Surgery for Valve Dysfunction, Death, and Moderate to Severe (3+) or Severe (4+) Mitral Regurgitation (MR) in Intention to Treat Strategy Cohort | 24 months | ||
| Secondary | Left Ventricular Ejection Fraction (LVEF) | LVEF as determined by the core echo laboratory at 30 days or hospital discharge, whichever is longer. | At discharge (= 14 days following index procedure) or 30 days | |
| Secondary | Left Ventricular Ejection Fraction (LVEF) | LVEF as determined by the core echo laboratory. | 12 months | |
| Secondary | Left Ventricular Ejection Fraction (LVEF) | LVEF as determined by the core echo laboratory. | 24 months | |
| Secondary | Left Ventricular Ejection Fraction (LVEF) | LVEF as determined by the core echo laboratory. | 3 years | |
| Secondary | Left Ventricular Ejection Fraction (LVEF) | LVEF as determined by the core echo laboratory. | 4 years | |
| Secondary | Left Ventricular Ejection Fraction (LVEF) | LVEF as determined by the core echo laboratory. | 5 years | |
| Secondary | Left Ventricular Status- Left Ventricular End-diastolic Volume (LVEDV), Left Ventricular End-systolic Volume (LVESV) | Left Ventricular Status includes Left ventricular (LV) end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 30 days or hospital discharge, whichever is longer. | 30 days | |
| Secondary | Left Ventricular Status- LVEDV, LVESV | Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV),as determined by the core echo laboratory at 12 months. | 12 months | |
| Secondary | Left Ventricular Status- LVEDV, LVESV | Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 24 months. | 24 months | |
| Secondary | Left Ventricular Status- LVEDV, LVESV | Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 3 years. | 3 years | |
| Secondary | Left Ventricular Status- LVEDV, LVESV | Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 4 years | 4 years | |
| Secondary | Left Ventricular Status- LVEDV, LVESV | Left Ventricular Status includes LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), as determined by the core echo laboratory at 5 years. | 5 years | |
| Secondary | Left Ventricular Internal Dimension Systole (LVIDs) | Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory. | 30 days | |
| Secondary | Left Ventricular Internal Dimension Systole (LVIDs) | Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory. | 12 months | |
| Secondary | Left Ventricular Internal Dimension Systole (LVIDs) | Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory. | 2 years | |
| Secondary | Left Ventricular Internal Dimension Systole (LVIDs) | Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory. | 3 years | |
| Secondary | Left Ventricular Internal Dimension Systole (LVIDs) | Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory. | 4 years | |
| Secondary | Left Ventricular Internal Dimension Systole (LVIDs) | Left Ventricular internal dimension systole (LVIDs) as determined by the core echo laboratory. | 5 years | |
| Secondary | Left Ventricular Internal Dimension Diastole (LVIDd) | Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory. | 30 days | |
| Secondary | Left Ventricular Internal Dimension Diastole (LVIDd) | Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 12 months. | 12 months | |
| Secondary | Left Ventricular Internal Dimension Diastole (LVIDd) | Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 24 months. | 24 months | |
| Secondary | Left Ventricular Internal Dimension Diastole (LVIDd) | Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 3 years. | 3 years | |
| Secondary | Left Ventricular Internal Dimension Diastole (LVIDd) | Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 4 years. | 4 years | |
| Secondary | Left Ventricular Internal Dimension Diastole (LVIDd) | Left Ventricular internal dimension diastole (LVIDd) as determined by the core echo laboratory at 5 years. | 5 years | |
| Secondary | Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease. | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
Baseline | |
| Secondary | Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease. | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
30 days | |
| Secondary | Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease. | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
12 months | |
| Secondary | Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease. | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
24 months | |
| Secondary | Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease. | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
3 years | |
| Secondary | Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease. | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
4 years | |
| Secondary | Number of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease. | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
5 years | |
| Secondary | New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
30 days | |
| Secondary | Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
12 months | |
| Secondary | Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
2 years | |
| Secondary | Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
3 years | |
| Secondary | Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
4 years | |
| Secondary | Percentage of Participants With New York Heart Association (NYHA) Functional Class Cardiac Disease: NYHA Functional Class III or IV | Class I: Patients with cardiac disease but without resulting limitations of physical activity. Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. |
5 years | |
| Secondary | Short Form (SF)-36 Quality of Life Questionnaire. | The SF-36 is a multidimensional, patient-reported survey containing 36 questions on a 0-100 scale measuring physical (Physical Component Score) & mental health status (Mental Component Score) in relation to 8 health concepts: physical functioning, role limitations due to physical or emotional health, bodily pain, general health perceptions, vitality, social functioning, & general mental health. Responses to each of the SF-36 items are scored and expressed as a score on a 0-100 scale (0% in a domain represents the poorest possible QOL&100% indicates full QOL).Higher scores represent better self-perceived health. The physical & mental functions were assessed by the Physical Component Summary (PCS) score & Mental Component Summary (MCS) score. Normal PCS and MCS scores vary depending on the demographics of the population studied. The PCS&MCS norms for 65-75 year old are 44 & 52, respectively while the norms for CHF population are 31 & 46, respectively. |
30 days | |
| Secondary | Short Form (SF)-36 Quality of Life Questionnaire. | The SF-36 is a multidimensional, patient-reported survey containing 36 questions on a 0-100 scale measuring physical (Physical Component Score) & mental health status (Mental Component Score) in relation to 8 health concepts: physical functioning, role limitations due to physical or emotional health, bodily pain, general health perceptions, vitality, social functioning, & general mental health. Responses to each of the SF-36 items are scored and expressed as a score on a 0-100 scale (0% in a domain represents the poorest possible QOL&100% indicates full QOL).Higher scores represent better self-perceived health. The physical & mental functions were assessed by the Physical Component Summary (PCS) score & Mental Component Summary (MCS) score. Normal PCS and MCS scores vary depending on the demographics of the population studied. The PCS&MCS norms for 65-75 year old are 44 & 52, respectively while the norms for CHF population are 31 & 46, respectively. |
12 months | |
| Secondary | Cardiac Output | Cardiac output as measured by core lab echocardiography. | 30 days | |
| Secondary | Cardiac Output | Cardiac output as measured by core lab echocardiography. | 12 months | |
| Secondary | Cardiac Output | Cardiac output as measured by core lab echocardiography. | 24 months | |
| Secondary | Cardiac Index | Defined as cardiac output divided by body surface area, as measured by core lab echocardiography. | 30 days | |
| Secondary | Cardiac Index (CI) | Defined as cardiac output divided by body surface area as measured by core lab echocardiography. CI is a normalization of cardiac output to take into account the effect of body size on cardiac output requirements. | 12 months | |
| Secondary | Cardiac Index | Defined as cardiac output divided by body surface area, as measured by core lab echocardiography. | 24 months | |
| Secondary | Regurgitant Volume | Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. | 30 Days | |
| Secondary | Regurgitant Volume | Regurgitant volume as determined by the core echo laboratory. | 12 months | |
| Secondary | Regurgitant Volume | Regurgitant volume as determined by the core echo laboratory. | 24 months | |
| Secondary | Regurgitant Fraction (RF) | RF is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium. | 30 Days | |
| Secondary | Regurgitant Fraction | Regurgitant fraction is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium. | 12 months | |
| Secondary | Regurgitant Fraction | Regurgitant fraction is defined as the percentage of the left ventricular (LV) stroke volume that regurgitates into the left atrium. | 24 months | |
| Secondary | Number of Participants With Clip Implant Rate | Defined as the rate of successful implantation of MitraClip(s). | Day 0 | |
| Secondary | Number of Participants With Acute Procedural Success | Defined as successful MitraClip implantation with resulting MR of 2+ or less. | 30 Days | |
| Secondary | Number of Participants With Acute Surgical Success | Defined as successful mitral valve repair or replacement surgery. | 30 Days | |
| Secondary | Number of Participants With Successful Clip Implant and Acute Procedural Success | Acute procedural success is defined as MR severity = 2 at discharge or 1 grade MR reduction at discharge accompanied by 1 level NYHA reduction. | 30 days | |
| Secondary | Number of Participants With Mitral Valve Repair Success. | Defined as freedom from mitral valve replacement surgery for Valve Dysfunction, death, re-operation, and MR > 2+ at 12 months. | 12 months | |
| Secondary | Number of Participants With Mitral Valve Repair Success. | Defined as freedom from mitral valve replacement surgery for Valve Dysfunction, death, re-operation, and MR > 2+ at 12 months. | 24 months | |
| Secondary | Number of Participants With Procedural Freedom From In-hospital MAE. | Day 0 | ||
| Secondary | Number of Participants With Procedural Freedom From In-hospital MAE | Day 30 | ||
| Secondary | Number of Participants With MAE: Surgery After Device and First Time Surgery Control | 30 days | ||
| Secondary | Number of Participants With Major Vascular Complications | Vascular Complications defined as the occurrence of any of the following resulting through 30 days or hospital discharge, whichever is longer: Hematoma at access site >6 cm; Retroperitoneal hematoma; Arteriovenous (AV) fistula; Symptomatic peripheral ischemia / nerve injury or the clinical signs or symptoms lasting >48 hours; Vascular Surgical Repair at catheter access sites; Pulmonary embolism; Ipsilateral deep vein thrombus; or Access site-related infection requiring intravenous antibiotics and/or extended hospitalization. |
30 days | |
| Secondary | Number of Participants With Major Vascular Complications | Vascular Complications defined as the occurrence of any of the following resulting through 30 days or hospital discharge, whichever is longer: Hematoma at access site >6 cm; Retroperitoneal hematoma; Arteriovenous (AV) fistula; Symptomatic peripheral ischemia / nerve injury or the clinical signs or symptoms lasting >48 hours; Vascular Surgical Repair at catheter access sites; Pulmonary embolism; Ipsilateral deep vein thrombus; or Access site-related infection requiring intravenous antibiotics and/or extended hospitalization. |
12 months | |
| Secondary | Number of Participants With Major Bleeding Complications. | Major Bleeding Complications defined as procedure related bleeding that requires a transfusion of =2 units of blood products and/or surgical intervention at 30 days or hospital discharge, whichever is longer. | 30 days | |
| Secondary | Number of Participants With Major Bleeding Complications. | Major Bleeding Complications defined as procedure related bleeding that requires a transfusion of =2 units of blood products and/or surgical intervention at 12 months. | 12 months | |
| Secondary | Number of Participants With Major Adverse Events (MAE) | 12 months. | ||
| Secondary | Number of Participants With MAE in Patients Over 75 Years of Age. | 30 days | ||
| Secondary | Number of Participants With MAE in Patients Over 75 Years of Age. | 12 months | ||
| Secondary | Number of Participants With Dysrhythmia | 30 days | ||
| Secondary | Number of Participants With Dysrhythmia | 12 months | ||
| Secondary | Number of Participants With Endocarditis. | Defined as a diagnosis of endocarditis based on the Duke criteria. Infection in the lining of the heart, of the valves, or of the muscles of the heart. Signs of endocarditis may include persistent positive blood cultures and/or valvular structural abnormality and vegetations as seen using echocardiography. | 30 days | |
| Secondary | Number of Participants With Endocarditis. | Defined as a diagnosis of endocarditis based on the Duke criteria. Infection in the lining of the heart, of the valves, or of the muscles of the heart. Signs of endocarditis may include persistent positive blood cultures and/or valvular structural abnormality and vegetations as seen using echocardiography. | 12 months | |
| Secondary | Number of Participants With Thrombosis. | Defined as evidence of the formation of an independently moving thrombus on any part of the MitraClip or any commercially available implant used during surgery by echocardiography or fluoroscopy. | 30 days | |
| Secondary | Number of Participants With Thrombosis. | Defined as evidence of the formation of an independently moving thrombus on any part of the MitraClip or any commercially available implant used during surgery by echocardiography or fluoroscopy. | 12 months | |
| Secondary | Number of Participants With Hemolysis | Defined as new onset of anemia associated with laboratory evidence of red cell destruction. Diagnosed when plasma free hemoglobin is greater than 40 mg/dL on repeat measures within 24 hours or on one measure if intervention is initiated based on other clinical symptoms. Reported as major or minor as defined below: Major: Requires intervention with red blood cell transfusion or other hematocrit increasing measures in the absence of other obvious bleeding. Minor: Does not require intervention. |
30 days | |
| Secondary | Number of Participants With Hemolysis | Defined as new onset of anemia associated with laboratory evidence of red cell destruction. Diagnosed when plasma free hemoglobin is greater than 40 mg/dL on repeat measures within 24 hours or on one measure if intervention is initiated based on other clinical symptoms. Reported as major or minor as defined below: Major: Requires intervention with red blood cell transfusion or other hematocrit increasing measures in the absence of other obvious bleeding. Minor: Does not require intervention. |
12 months | |
| Secondary | Number of Participants With Clinically Significant Atrial Septal Defect (ASD). | Defined as a significant residual atrial septal opening. Reported as clinically significant if intervention is performed for the primary purpose of repairing the ASD. If cardiac surgery is indicated for reasons other than residual ASD (e.g., residual MR) and the ASD is repaired at the same time, this does not meet the definition of clinically significant ASD. | 30 days | |
| Secondary | Number of Participants With Clinically Significant Atrial Septal Defect (ASD) | Defined as a significant residual atrial septal opening. Reported as clinically significant if intervention is performed for the primary purpose of repairing the ASD. If cardiac surgery is indicated for reasons other than residual ASD (e.g., residual MR) and the ASD is repaired at the same time, this does not meet the definition of clinically significant ASD. | 12 months | |
| Secondary | Number of Participants With Mitral Valve Stenosis | Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. | 30 days | |
| Secondary | Number of Participants With Mitral Valve Stenosis | Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. | 12 months | |
| Secondary | Number of Participants With Mitral Valve Stenosis | Defined as a mitral valve planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. | 24 months | |
| Secondary | Number of Participants With Mitral Valve Stenosis | Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A "confirmed" case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area < 1.5 cm^2. A "conservative" case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms. | 3 years | |
| Secondary | Number of Participants With Mitral Valve Stenosis | Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A "confirmed" case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area < 1.5 cm^2. A "conservative" case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms. | 4 years | |
| Secondary | Number of Participants With Mitral Valve Stenosis | Defined as a mitral valve (MV) planimetered orifice area of less than 1.5 cm^2 as measured by echocardiography. A "confirmed" case of MV stenosis is defined as Echocardiography Core Lab (ECL) measured mitral valve orifice area < 1.5 cm^2. A "conservative" case of MV stenosis is defined as stenosis suspected by the site, based on hemodynamic measurements or clinical symptoms. | 5 years | |
| Secondary | Mitral Valve Area by Planimetry | Mitral valve area as measured by core lab echocardiography. | At Discharge (=14 days of index procedure) | |
| Secondary | Mitral Valve Area by Planimetry | Mitral valve area as measured by core lab echocardiography. | 30 Days | |
| Secondary | Mitral Valve Area by Planimetry | Mitral valve area as measured by core lab echocardiography. | 12 months | |
| Secondary | Mitral Valve Area by Planimetry | Mitral valve area as measured by core lab echocardiography. | 24 months | |
| Secondary | Mitral Valve Area by Planimetry | Mitral valve area as measured by core lab echocardiography. | 3 years | |
| Secondary | Mitral Valve Area by Planimetry | Mitral valve area as measured by core lab echocardiography. | 4 years | |
| Secondary | Mitral Valve Area by Planimetry | Mitral valve area as measured by core lab echocardiography. | 5 years | |
| Secondary | Mitral Valve Area by Planimetry Index | Defined as mitral valve area divided by body surface area as measured by core lab echocardiography. | 30 Days | |
| Secondary | Mitral Valve Area by Planimetry Index | Defined as mitral valve area divided by body surface area as measured by core lab echocardiography. | 12 months | |
| Secondary | Mitral Valve Area by Planimetry Index | Defined as mitral valve area divided by body surface area as measured by core lab echocardiography. | 24 months | |
| Secondary | Mitral Valve Area by Pressure Half-time | Mitral valve area as measured by core lab echocardiography. | At Discharge (=14 days of index procedure) | |
| Secondary | Mitral Valve Area by Pressure Half-time | Mitral valve area as measured by core lab echocardiography. | 30 days | |
| Secondary | Mitral Valve Area by Pressure Half-time | Mitral valve area as measured by core lab echocardiography. | 12 months | |
| Secondary | Mitral Valve Area by Pressure Half-time | Mitral valve area as measured by core lab echocardiography. | 24 months | |
| Secondary | Mitral Valve Area by Pressure Half-time | Mitral valve area as measured by core lab echocardiography. | 3 years | |
| Secondary | Mitral Valve Area by Pressure Half-time | Mitral valve area as measured by core lab echocardiography. | 4 years | |
| Secondary | Mitral Valve Area by Pressure Half-time | Mitral valve area as measured by core lab echocardiography. | 5 years | |
| Secondary | Mitral Valve Area by Pressure Half-time Index | Defined as mitral valve area divided by body surface area as measured by core lab echocardiography. | 30 Days | |
| Secondary | Mitral Valve Area by Pressure Half-time Index | Defined as mitral valve area divided by body surface area as measured by core lab echocardiography. | 12 months | |
| Secondary | Mitral Valve Area by Pressure Half-time Index | Defined as mitral valve area divided by body surface area as measured by core lab echocardiography. | 24 months | |
| Secondary | Transvalvular Mitral Valve Gradient | Defined as the mean pressure gradient across the mitral valve as measured by echocardiography. | At Discharge (= 14 days following index procedure) | |
| Secondary | Transvalvular Mitral Mean Pressure Gradient (Mean MVG) | Defined as the mean pressure gradient across the mitral valve as measured by Echocardiography Core Laboratory (ECL). | 12 months | |
| Secondary | Transvalvular Mitral Mean Pressure Gradient (Mean MVG) | Defined as the mean pressure gradient across the mitral valve as measured by echocardiography. | 24 months | |
| Secondary | Transvalvular Mitral Mean Pressure Gradient (Mean MVG) | Defined as the mean pressure gradient across the mitral valve as measured by echocardiography. | 3 year | |
| Secondary | Transvalvular Mitral Mean Pressure Gradient (Mean MVG) | Defined as the mean pressure gradient across the mitral valve as measured by echocardiography. | 4 year | |
| Secondary | Transvalvular Mitral Mean Pressure Gradient (Mean MVG) | Defined as the mean pressure gradient across the mitral valve as measured by echocardiography. | 5 years | |
| Secondary | Post-procedure Length of Hospital Stay | 30 Days | ||
| Secondary | Post-procedure Intensive Care Unit (ICU) / Critical Care Unit (CCU) Duration | 30 Days | ||
| Secondary | Number of Participants With Hospital Re-admissions | Defined as re-admission to the hospital for any reason. The endpoint was intended to capture each time a patient was re-admitted to the hospital for any reason and was to be reported as a rate through 30 days for both the Device and Control groups. | 30 days | |
| Secondary | Number of Participants With Incidence of Discharge to a Nursing Home or Skilled Nursing Facility/Hospital | 30 Days | ||
| Secondary | Number of Participants With Incidence of Hospital Readmissions for Congestive Heart Failure (CHF). | 30 days | ||
| Secondary | Number of Participants With New Coumadin (Warfarin) Usage | 30 days | ||
| Secondary | Number of Participants With New Coumadin (Warfarin) Usage | 12 months | ||
| Secondary | Number of Participants With Durability of the MitraClip Device and Surgery. | Device group: Freedom from death, surgery for mitral valve dysfunction and MR > 2+ at the end of each follow-up interval. Control group: Freedom from death, re-operation for mitral valve dysfunction and MR > 2+ at the end of each follow-up interval. |
12 months | |
| Secondary | Number of Participants With Durability of the MitraClip Device and Surgery. | Device group: Freedom from death, surgery for mitral valve dysfunction and MR > 2+ at the end of each follow-up interval. Control group: Freedom from death, re-operation for mitral valve dysfunction and MR > 2+ at the end of each follow-up interval. |
12-18 months | |
| Secondary | Number of Participants With Durability of the MitraClip Device and Surgery. | Device group: Freedom from death, surgery for mitral valve dysfunction and MR > 2+ at the end of each follow-up interval. Control group: Freedom from death, re-operation for mitral valve dysfunction and MR > 2+ at the end of each follow-up interval. |
18-24 months | |
| Secondary | Number of Participants With Durability of the MitraClip Device and Surgery. | Device group: Freedom from death, surgery for mitral valve dysfunction and MR > 2+ at the end of each follow-up interval. Control group: Freedom from death, re-operation for mitral valve dysfunction and MR > 2+ at the end of each follow-up interval. |
24 months-3 year | |
| Secondary | Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR > 2+ | Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR > 2+ | 12 months | |
| Secondary | Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR > 2+ | Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR > 2+ | 24 months | |
| Secondary | Number of Participants With Freedom From Death, Mitral Valve Surgery/Re-operation and MR > 2+ | Durability estimates: Freedom from Death, Mitral Valve Surgery/Re-operation and MR > 2+ | 3 years | |
| Secondary | Number of Participants With Freedom From Mitral Valve Surgery/Re-operation | Durability estimates: Freedom from Mitral Valve Surgery/Re-operation | 12 months | |
| Secondary | Number of Participants With Freedom From Mitral Valve Surgery/Re-operation | Durability estimates: Freedom from Mitral Valve Surgery/Re-operation | 24 months | |
| Secondary | Number of Participants With Freedom From Mitral Valve Surgery/Re-operation | Durability estimates: Freedom from Mitral Valve Surgery/Re-operation | 3 years | |
| Secondary | Number of Participants With Freedom From Mitral Valve Surgery/Re-operation | Durability estimates: Freedom from Mitral Valve Surgery/Re-operation | 4 years | |
| Secondary | Number of Participants With Freedom From Mitral Valve Surgery/Re-operation | Durability estimates: Freedom from Mitral Valve Surgery/Re-operation | 5 years | |
| Secondary | Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation | Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation | 12 months | |
| Secondary | Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation | Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation | 24 months | |
| Secondary | Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation | Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation | 3 years | |
| Secondary | Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation | Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation | 4 years | |
| Secondary | Number of Participants With Freedom From Death and Mitral Valve Surgery/Re-operation | Durability estimates: Freedom from Death and Mitral Valve Surgery/Re-operation | 5 years | |
| Secondary | Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment | Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device. | 12 months | |
| Secondary | Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment | Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device | 12 months to 3 years | |
| Secondary | Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment | Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device | 12 months to 4 years | |
| Secondary | Number of Participants With MitraClip Device Embolization/Single Leaflet Device Attachment | Device Embolization is defined as the complete detachment of the MitraClip Device from one or both mitral leaflets. Single leaflet device attachment (SLDA) is defined as attachment of one mitral valve leaflet to the MitraClip device. The control group did not receive the MitraClip device | 12 months to 5 years | |
| Secondary | Number of Participants With Non-cerebral Thromboembolism. | Defined as any thrombus or thromboembolism in the vasculature (excluding central nervous system events) or on the investigational device or any commercially available implant used during surgery confirmed by standard clinical and laboratory testing and which requires treatment. | 12 months | |
| Secondary | Number of Participants With MR Severity | MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe. "Discharge" refers to each individual patient's date of hospital discharge. The discharge date varies for each patient, but in general, discharge occurs before 30-days follow-up. A 30-day echocardiogram will be used if the discharge echocardiogram is unavailable or otherwise uninterpretable. |
30 days | |
| Secondary | Number of Participants With MR Severity | MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe | 12 months | |
| Secondary | Number of Participants With MR Severity | MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe | 24 months | |
| Secondary | Number of Participants With MR Severity | MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe | 3 years | |
| Secondary | Number of Participants With MR Severity | MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe | 4 years | |
| Secondary | Number of Participants With MR Severity | MR Severity of 0: None,1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe | 5 years | |
| Secondary | Number of Participants With Non-cerebral Thromboembolism. | Defined as any thrombus or thromboembolism in the vasculature (excluding central nervous system events) or on the investigational device or any commercially available implant used during surgery confirmed by standard clinical and laboratory testing and which requires treatment. | 30 days | |
| Secondary | Number of Participants With Incidence of Mitral Valve Replacement | 12 months | ||
| Secondary | Number of Participants With Incidence of Mitral Valve Replacement | 24 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03278574 -
Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease
|
N/A | |
| Suspended |
NCT04960280 -
A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease
|
N/A | |
| Recruiting |
NCT05021614 -
Valveclip® Transcatheter Mitral Valve Repair Study
|
N/A | |
| Not yet recruiting |
NCT06465745 -
AltaValve Pivotal Trial
|
N/A | |
| Not yet recruiting |
NCT06167213 -
ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
|
N/A | |
| Withdrawn |
NCT05040451 -
Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation
|
||
| Withdrawn |
NCT03714412 -
Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System
|
N/A | |
| Recruiting |
NCT02592889 -
(MitraClip in Non-Responders to Cardiac Resynchronization Therapy)
|
Phase 4 | |
| Completed |
NCT02355418 -
The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
|
||
| Completed |
NCT01841554 -
Cardioband With Transfemoral Delivery System
|
N/A | |
| Not yet recruiting |
NCT01431222 -
Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery
|
Phase 4 | |
| Not yet recruiting |
NCT03870516 -
Left Chamber Function in Mitral Regurgitation and Predicting Outcome After Replacement and Targeting for Early Surgery
|
N/A | |
| Active, not recruiting |
NCT03230747 -
SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation
|
N/A | |
| Enrolling by invitation |
NCT04031274 -
Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry
|
||
| Completed |
NCT05836532 -
Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
|
||
| Completed |
NCT05850026 -
Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
|
||
| Completed |
NCT05836480 -
Immediate Suboptimal Result of Mitral Valve Repair: Late Implications in a Matched Cohort Study
|
||
| Recruiting |
NCT03975998 -
Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation
|
||
| Completed |
NCT01162083 -
Identifying an Ideal Cardiopulmonary Exercise Test Parameter
|
N/A | |
| Suspended |
NCT00787293 -
Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients
|
Phase 2 |